GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals

More

  • Biotech land grab in Kendall Square   Thursday, 30 Apr 2015 | 2:56 PM ET
    Biotech companies expand in Kendall Square

    CNCB's Meg Tirrell reports on one of the biotechnology industry's capital cities. 130 life sciences companies occupy Kendall Square in Cambridge, Massachusetts.

  • Biotech boom land grab   Thursday, 30 Apr 2015 | 2:56 PM ET
    Biotech boom land grab

    Real estate in Kendall Square is exploding, where biotech and big pharma companies are finding homes. Joel Marcus, Alexandria Real Estate CEO, discusses what's driving the real estate boom in the area.

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • Cost in health profile in US is not sustainable: Cigna CEO

    David Cordani, Cigna CEO, discusses Cigna's business strategy, the high price of drugs, and Obamacare.

  • Biotech's real estate boom   Thursday, 30 Apr 2015 | 6:23 AM ET
    Biotech's real estate boom

    CNBC's Meg Tirrell reports the boom in biotechnology is prompting a hunt for real estate in the Boston area, squeezing rents and forcing vacancy rates to historic lows.

  • Ariad CEO to retire in deal with activist Sarissa Wednesday, 29 Apr 2015 | 7:10 AM ET
    A chemist works in the lab of Ariad Pharmaceuticals.

    Ariad Pharmaceuticals' CEO will retire this year in a settlement with hedge fund Sarissa Capital, capping months of agitation.

  • Biogen takes on Alzheimer's   Tuesday, 28 Apr 2015 | 4:29 PM ET
    alzheimer's

    George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.

  • Optimism for the future of biotech Tuesday, 28 Apr 2015 | 4:27 PM ET
    Biotech

    The manager of Fidelity Biotech's portfolio is optimistic about the future of biotech as he sees a continuous attempt to innovate.

  • Reason to be optimistic in biotech: Pro   Tuesday, 28 Apr 2015 | 1:39 PM ET
    Reason to be optimistic in biotech: Pro

    Rajiv Kaul, Fidelity biotech portfolio manager, discusses long term investing and why he is optimistic about the biotech sector going forward.

  • Dollar hits Pfizer; Merck 'blew away' estimates Tuesday, 28 Apr 2015 | 9:04 AM ET
    Tablets of Pfizer Inc.'s Lipitor and Merck & Co.'s Zocor.

    Pfizer reported a 4 percent drop in quarterly revenue, while Merck posted earnings that topped expectations.

  • Mylan/Perrigo, a more likely combination: Pro   Friday, 24 Apr 2015 | 1:16 PM ET
    Mylan/Perrigo, a more likely combination: Pro

    Fred Hassan, Warburg Pincus Partner and Managing Director, discusses the latest pharmaceutical deals making headlines and believes Mylan and Perrigo are the most complementary for a deal.

  • Mylan lowers price for Perrigo   Friday, 24 Apr 2015 | 10:37 AM ET
    Mylan lowers price for Perrigo

    CNBC's David Faber reports on pharmaceutical acquisitions making headlines including Mylan and Perrigo.

  • Why investors are putting money in Europe   Thursday, 23 Apr 2015 | 4:40 AM ET
    Why investors are putting money in Europe

    Evan Schoenbach, early stage tech investor at Mosaic Ventures, says there are several great reasons why investment is flowing into Europe right now.

  • Is Sony finally reaping restructuring results?   Wednesday, 22 Apr 2015 | 8:34 PM ET
    Is Sony finally reaping restructuring results?

    Damian Thong, division director and senior analyst of Japan Technology at Macquarie Securities, discusses news that Sony raised its earnings estimates for the second time in three months on Wednesday.

  • The love-hate triangle in pharma   Wednesday, 22 Apr 2015 | 2:09 PM ET
    The love-hate triangle in pharma

    Corey Davis, Canaccord Genuity, discusses big deals in pharmaceutical including Teva's bid for Mylan.

  • Abbott posts profit beat   Wednesday, 22 Apr 2015 | 2:07 PM ET
    Abbott posts profit beat

    CNBC's Meg Tirrell reports on Abbott Laboratories' earnings and deals associated with this company.

  • More M&A to come in biotech, pharma?   Wednesday, 22 Apr 2015 | 5:15 AM ET
    More M&A to come in biotech, pharma?

    David Seaburg, head of sales trading at Cowen and Company, explains why there's more M&A to come in the biotech and pharmaceutical sector.

  • Amgen handily beats Street on strong drug sales Tuesday, 21 Apr 2015 | 4:36 PM ET
    Amgen

    Amgen's product sales rose 12 percent as the company easily beat Wall Street's first-quarter earnings and revenue estimates.

  • Biotech buyout? Teva's $40 billion bid   Tuesday, 21 Apr 2015 | 3:30 PM ET
    Biotech buyout? Teva's $40 billion bid

    Teva is offering $40 billion to buy Mylan. Barbara Ryan, Clemont Partners, and CNBC's Meg Tirrell, provide perspective on the potential consolidation.

  • New evidence clears measles vaccine of autism link Tuesday, 21 Apr 2015 | 11:00 AM ET
    A doctor prepares to administer a measles vaccination to a child.

    A study of 95,000 kids found absolutely no link between the measles vaccine and autism, even in children with autistic siblings.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.